Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMN440
- Development stage
- Preclinical
- Lead developer
- ProMIS Neurosciences
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular (preclinical Data; Typical For Vaccines)
01
Overview
PMN440 is a therapeutic vaccine in preclinical development by ProMIS Neurosciences. It is designed to target synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The vaccine uses computationally-derived conformational B cell epitopes to selectively induce high-affinity antibodies against pathogenic species of alpha-synuclein (toxic oligomers and small soluble seeding fibrils), while sparing normal alpha-synuclein function. This selectivity aims to maximize efficacy and minimize off-target effects by avoiding pan-alpha-synuclein reactivity[6][10]. Preclinical studies have demonstrated that vaccination with these epitopes produces the desired antibody response in animal models[6].
- Other names
- PMN-400PMN400PMN 400PMN-440PMN440PMN 440alpha-synuclein conformational B cell epitope vaccine
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on PMN440.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMN440.